Trade

Suven Life Sciences share price

High risk
  • 46%Low risk
  • 46%Moderate risk
  • 46%Balanced risk
  • 46%High risk
  • 46%Extreme risk
  • 169.45(-1.14%)
    December 5, 2025 15:28:00 PM IST
    • NSE
    • BSE
  • Vol : 274.58 K (NSE + BSE)
    Last 20 day avg : 172.57 K

Suven Life Sciences is trading -1.14% lower at Rs 169.45 as compared to its last closing price. Suven Life Sciences has been trading in the price range of 175.45 & 165.00. Suven Life Sciences has given 34.15% in this year & -1.17% in the last 5 days. The company posted a net profit of -77.31 Crores in its last quarter.Listed peers of Suven Life Sciences include Divi's Laboratories (-0.04%), Sun Pharmaceutical Industries (-0.75%), Torrent Pharmaceuticals (-0.74%).The Mutual Fund holding in Suven Life Sciences was at 2.08% in 30 Sep 2025. The MF holding has decreased from the last quarter. The FII holding in Suven Life Sciences was at 1.17% in 30 Sep 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Dec 07, 2025, 05:18 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    1.08
    Medium volatility
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.00
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    34.02
    Higher than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    -
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    -
Price range
Day Range
Lowest
165.00
Highest
175.45
52 week range
Lowest
102.70
Highest
303.00
Suven Life Sciences Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Divi's Laboratories
Bullish
6,468.25-0.041,73,113.6278.2711.470.460.01
Sun Pharmaceutical Industries
Bullish
1,805.00-0.754,33,140.8537.946.040.880.50
Torrent Pharmaceuticals
Bullish
3,773.70-0.741,27,661.9766.6416.920.8417.62
Dr Reddy's Laboratories
Bullish
1,276.55-0.041,06,330.4218.803.170.632.34
Cipla
Neutral
1,520.55-0.041,22,825.6523.333.940.850.81
Mutual Fund Ownership
View all
Bandhan BSE Healthcare Index Fund Regular Growth
NA
  • Amount Invested (Cr.) 0.03
  • % of AUM 0.12
Suven Life Sciences Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-11-11Quarterly Results
2025-08-13Quarterly Results
2025-05-13Audited Results & Preferential issue
2025-01-24Quarterly Results
2024-10-29Quarterly Results
About the company Suven Life Sciences
  • IndustryBiotechnology & Drugs
  • ISININE495B01038
  • BSE Code530239
  • NSE CodeSUVEN
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
  • Management Info
  • Venkateswarlu JastiExecutive Chairman of the Board, Managing Director
  • M. Mohan KumarChief Financial Officer
  • Shrenik SoniChief Compliance Officer, Company Secretary
  • Sudha JastiWholetime Director
Suven Life Sciences Share Price FAQs

Suven Life Sciences is trading at 169.45 as on Fri Dec 05 2025 09:58:00. This is -1.14% lower as compared to its previous closing price of 171.40.

The market capitalization of Suven Life Sciences is 3857.93 Cr as on Fri Dec 05 2025 09:58:00.

The 52 wk high for Suven Life Sciences is 303.00 whereas the 52 wk low is 102.70

Suven Life Sciences can be analyzed on the following key metrics -

  • TTM P/E:
  • Sector P/E: -
  • Dividend Yield: 0.00%
  • D/E ratio: 0.00

Suven Life Sciences reported a net profit of -160.75 Cr in 2025.

The Mutual Fund Shareholding was 2.08% at the end of 30 Sep 2025.